



NO. SO(RMC)2-21/2025
GOVERNMENT OF THE PUNJAB
SPECIALIZED HEALTHCARE &
MEDICAL EDUCATION DEPARTMENT
(TECHNICAL WING)

Dated Lahore, the 6th January, 2026

To

1. Vice Chancellors of all public sector Medical Universities in Punjab
2. Principals / Deans / EDs of all public sector Medical Colleges / Specialized Medical Institutions in Punjab
3. Medical Superintendents of all public sector Teaching Hospitals in Punjab

Subject: DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

I am directed to refer the subject cited above and to enclose herewith copy of a letters No. 13-30/2024-DD(QA-VIII) dated 18.12.2025 received from the Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad.

2. Submitted for information and further necessary action.


SECTION OFFICER (RMC)

NO & DATE EVEN:

Copy is forwarded for information to the:

1. Deputy Director-IX (QA & LT), Drug Regulatory Authority of Pakistan, Division of Quality Assurance & Laboratory Testing, Prime Minister's National Health Complex, Islamabad w/r to letter referred above.
2. PSO to Secretary to Government of the Punjab, Specialized Healthcare & Medical Education Department.
3. PS to Special Secretary (Operations), Specialized Healthcare & Medical Education Department.
4. P.A. to Additional Secretary (Technical), Specialized Healthcare & Medical Education Department.

SECTION OFFICER (RMC)



13-30/2024-DD(QA-VIII)
Government of Pakistan
Drug Regulatory Authority of Pakistan
Division of Quality Assurance & Laboratory Testing
Prime Minister's National Health Complex, Islamabad.

MOST IMMEDIATE

Islamabad, the 18th December, 2025.

Subject: DRUG PRODUCTS DECLARED SUBSTANDARD BY PROVINCIAL DRUG TESTING LABORATORIES.

I am directed to refer to the subject cited above and reports received from Government of Gilgit Baltistan wherein below mentioned Drug Products declared 'Substandard' quality. Details of products are as under:

S#	Product Name	Batch No.	Remarks	Manufacturers
1.	Glitric Tablets Each prolonged release tablet contains: Glyceryl Trinitrate 2.6 mg (Reg. # 119607)	25H261 & 25H262	Batch # 25H261 The sample has been declared "Substandard" on the basis of Assay & Dissolution Test. Batch # 25H262 The sample has been declared "Substandard" on the basis of Assay Test.	M/s Linta Pharmaceuticals. Plot # 03, Street S-5, National Industrial Zone, Rawat, Islamabad. (DML # 000810)
2.	Betahist Tablet Each Tablet contains: Betahistine DiHydrochloride ... 16 mg (Reg. 091595)	25H249	The sample has been declared "Substandard" on the basis of Physical description. (Tablets found with softening, cracking, rough orange peel texture, easily break, and become powder when pressed with fingers).	

2. The above mentioned firm is hereby directed to immediately alert your sales officers/suppliers/distributors to issue instructions to the distributors, for the return of suspected stocks of the above mentioned batch of the product & within three working (03) days, you are directed to submit 'Recall Assessment Form' to this division in light of guidance provided in the "Guidelines on Recall of Defective Therapeutic Goods (Edition 02)" available on DRAP's website i.e. <https://www.dra.gov.pk/wp-content/uploads/2024/11/Recall-Guidelines-Edition-2-V1-1-Final-08-10-2024-1-2.pdf>.

(SALATEEN WASEEM PHILIP)
Deputy Director-IX (QA<)

Copy for information and necessary action – with request to issue necessary directions to points of use/sale under administrative control/ fall under area of jurisdiction to ensure recall of defective product from the market, please.

1. The Secretary (SHC&ME) Health Department (Government of Punjab).
2. The Secretary Population Welfare Department (Government of Punjab).
3. The Secretary Health Department (Government of Sindh).
4. The Secretary Health Department (Government of KP).
5. The Secretary Health Department (Government of Baluchistan).
6. The Secretary, Health Department (Government of AJ&K).
7. The Secretary, Health Department (Government of Gilgit Baltistan).
8. The Additional Director / Office In-charge, DRAP, Lahore, Karachi, Islamabad, Peshawar, and Quetta.
9. The Chief Drug Controller / Inspector Punjab, Sindh, Khyber Pakhtunkhwa, Baluchistan, AJ&K, GB and ICT with request to oversight recall at distributor level and sales point.

Copy to:-

- i. Area FID, to coordinate with concerned manufacturer regarding oversight of the recall process within the required time.
- ii. Office copy

Deputy Director - IX (QA<)